Litigation Details for Federal Trade Commission v. U.S. Anesthesia Partners, Inc. (S.D. Tex. 2023)
✉ Email this page to a colleague
Federal Trade Commission v. U.S. Anesthesia Partners, Inc. (S.D. Tex. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-09-21 |
| Court | District Court, S.D. Texas | Date Terminated | |
| Cause | 15:0045 Federal Trade Commission Act | Assigned To | Kenneth M. Hoyt |
| Jury Demand | None | Referred To | |
| Patents | 6,503,894; RE37,516 | ||
| Link to Docket | External link to docket | ||
Details for Federal Trade Commission v. U.S. Anesthesia Partners, Inc. (S.D. Tex. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-01-19 | 119 | Second Appendix of Authorities | No. 6,503,894 ('894 patent). Although exclusivity upon FDA approval, which is similar to…Generics within the forty-five day window of patent, drug patents grant brand name manufacturers a legal … a similar schedule. FDA, (2) the patent has expired, (3) the patent will expire on a …holder of the ANDA. 6 If the patent holder decides to file patent as well as claims construction…issued a patent on ANDA with a Paragraph IV certification receives generic AndroGel, U.S. Patent No. | External link to document |
| 2023-11-06 | 81 | Appendix Appendix of Authorities | particles. This patent first issued in 1997 and re-issued in 2002 as U.S. Patent No. RE37,516 (the “Particle…notify the patent holder of the filing of its ANDA. If the patent holder initiates a patent infringement… only then-remaining patent that covered Provigil, a narrow formulation patent relating to the size of…version does not infringe the patents on the brand-name drug, or (2) the patents are invalid. This is referred… the earliest of (1) patent expiry, (2) district court resolution of the patent litigation in favor of | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
